Kentucky SB 21: AN ACT relating to use of experimental treatments for terminal illnesses. Create new sections of KRS Chapter 217 to define terms; permit eligible patients to use investigational drugs, biological products, or devices for a terminal illness; establish the conditions for use of such experimental treatments; prohibit sanctions of health care providers; clarify the duties of health care insurers regarding experimental treatments; prohibit certain actions by state officials.

Status: Signed by Governor (Acts, ch. 65) (as of 2017-03-21)

State: Kentucky · Session: 2017RS · Bill: SB 21

View Kentucky SB 21 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.